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Abstract
Reflecting the change in funding strategies for European re-
search projects, and the goal to jointly improve medical radi-
ation protection through sustainable research efforts, five
medical societies involved in the application of ionising radi-
ation (European Association of Nuclear Medicine, EANM;
European Federation of Organizations for Medical Physics.
EFOMP; European Federation of Radiographer Societies,
EFRS; European Society of Radiology, ESR; European
Society for Radiotherapy and Oncology, ESTRO) have iden-
tified research areas of common interest and developed this
first edition of the Common Strategic Research Agenda
(SRA) for medical radiation protection.
The research topics considered necessary and most urgent
for effective medical care and efficient in terms of radiation
protection are summarised in five main themes:
1. Measurement and quantification in the field of medical
applications of ionising radiation
2. Normal tissue reactions, radiation-induced morbidity and
long-term health problems
3. Optimisation of radiation exposure and harmonisation of
practices
4. Justification of the use of ionising radiation in medical
practice
5. Infrastructures for quality assurance
The SRA is a living document; thus comments and
suggestions by all stakeholders in medical radiation protec-
tion are welcome and will be dealt with by the European
Alliance for Medical Radiation Protection Research
(EURAMED) established by the above-mentioned
societies.
Main messages
•Overcome the fragmentation of medical radiation protection
research in Europe
• Identify research areas of joint interest in the field of medical
radiation protection
• Improve the use of ionising radiation in medicine
• Collect stakeholder feedback and seek consensus
• Emphasise importance of clinical translation and evaluation
of research results
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Preamble
Reflecting the changing funding strategies of research
projects within Europe and the goal of jointly improving
medical care by sustainable research efforts, the following
medical societies involved in the application of ionising
radiation, namely,
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European Association of Nuclear Medicine (EANM)
The EANM is the umbrella organisation representing
nuclear medicine in Europe and represents 40 National
Member Societies, approximately 3200 individual
members and around 30,000 professionals working in
Nuclear Medicine in Europe. EANM aims to advance
science and education in nuclear medicine for the bene-
fit of public health, relating to the diagnosis, treatment,
research and prevention of diseases through the use of
unsealed radioactive substances and the properties of
stable nuclides in medicine, throughout Europe.
European Federation of Organisations for Medical
Physics (EFOMP)
The EFOMP serves as an umbrella organisation
representing 35 national member and affiliated organi-
sations of more than 7000 physicists and engineers
working in the field of medical physics in Europe.
EFOMP aims to harmonise and advance medical physic
in both its professional clinical and scientific expression
throughout Europe by bringing about and maintaining
systematic exchange of professional and scientific infor-
mation, through the formulation of common policies,
and by promoting education and training programmes.
European Federation of Radiographer Societies
(EFRS)
The EFRS is the non-profit umbrella organisation
representing 39 professional societies and 51 education-
al institutions representing over 100,000 radiographers
across Europe. The aims of the EFRS are to represent,
promote and develop the profession of radiography in
Europe, across medical imaging, nuclear medicine and
radiotherapy areas of radiography practice.
European Society of Radiology (ESR)
The ESR is a non-profit organisation representing the
general interests of radiology in Europe. The aims of
ESR are to serve the healthcare needs of the general pub-
lic through the support of science, teaching and research
and the quality of service in the field of radiology as well
as the promotion and coordination of the scientific, phil-
anthropic, intellectual and professional activities of radi-
ology in all European countries. The ESR has over
69,300 individual members as well as 59 institutional
member societies of which 44 are national radiology so-
cieties and 15 are European Radiological Subspecialty
Societies and European Allied Sciences Societies.
European Society for Radiotherapy and Oncology
(ESTRO)
The ESTRO is a non-profit scientific organisation
representing radiation oncologists, medical physicists,
radiobiologists and radiation therapists with over 5000
members both within and outside Europe. ESTRO aims
to foster the role of radiation oncology in order to im-
prove patient care in the multimodality treatment of
cancer by promoting innovation, research and dissemi-
nation of science through its congresses, special meet-
ings, educational courses and publications.
decided that it was necessary and would be helpful to
develop a corresponding common Medical Strategic
Research Agenda (Medical SRA) to overcome current
and future deficits and to be a constructive partner in
European radiation protection research. To this end, re-
search areas of interest have been jointly identified and
agreed upon in this common SRA endorsed by the med-
ical societies.
The effort of the medical societies in developing an SRA
for the medical application of ionising radiation complements
the efforts of other European platforms such as MELODI,
EURADOS, ALLIANCE and NERIS, which have developed
or are developing their own SRAs in the fields of general low-
dose research, dosimetry, radioecology and emergency pre-
paredness, respectively.
In a memorandum of understanding (MoU) signed by the
medical societies, MELODI and EURADOS in 2014, it was
decided to cooperate in order to promote the integration and
the efficiency of European radiation protection research, to
maintain and use a common European infrastructure for this
research as well as to bring forward scientific education and
training in the field of radiation protection for medical appli-
cations of ionising radiations.
The mission is to achieve the following objectives:
& Ensure an adequate level of information exchange be-
tween the signatories in the fields of joint interest within
the scope of the MoU;
& Identify gaps of joint interest in existing SRAs with re-
spect to RTD needs for improving radiation protection in
the medical field, or for improving the effectiveness/
exposure ratio of medical protocols based on the use of
ionising radiations, so as to optimise the SRA contents and
avoid duplication of efforts;
& Identify research areas of joint interest where progress
may benefit from contributions from signatory organisa-
tions, or the members thereof, e.g. some low-dose effects
or dosimetry research projects may benefit from contribu-
tions in a clinical environment, conversely, some medical
protocol researchmay benefit from advanced dosimetry or
radiobiology developments;
& Develop joint documents to support the elaboration of
research and technological development (RTD) calls
in the framework of the Horizon 2020 programme,
both in the EURATOM/Fission and in the Health
programmes;
& Optimise and coordinate the dissemination of scientific
knowledge resulting from research, particularly through
education and training actions.
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The stakeholders are involved through a formal consulta-
tion process that has been initiated, is ongoing and will be
reflected in future updates of the SRA presented here.
Summary
Reflecting the change of funding strategies for research pro-
jects within Europe, and the goal of jointly improving medical
care by sustainable research efforts, the medical societies in-
volved in the application of ionising radiation have identified
research areas of interest and agreed upon these in this com-
mon SRA endorsed by the medical societies.
The research that is seen to be necessary and most urgent
for effective medical care, under the best harmonised practice,
and efficient in terms of radiation protection can be
summarised to the following five main topics:
1. Measurement and quantification in the field of medical
applications of ionising radiation
2. Normal tissue reactions, radiation-induced morbidity and
long-term health problems
3. Optimisation of radiation exposure and harmonisation of
practices
4. Justification of the use of ionising radiation in medical
practice
5. Infrastructures for quality assurance
The subtopics defined for each topic describe the specific
research aspects that are identified as areas of great importance
regarding research for establishing optimal radiation protec-
tion in the field of medical applications. These descriptions
can be found in Chap. 3.
It is important to highlight that the approach to improve the
use of ionising radiation in medicine by pure fundamental
research would lack impact and influence unless having im-
mediate consequences for and being translatable to everyday
clinical practice. It is also important that the results of the
research are not only translatable but really translated into
daily routines. Therefore it is essential that the research is
undertaken in a concise manner by persons educated and
trained for good medical practice. The results have to be eval-
uated in clinical practice and have to be made public in a way
that it is easy to access (results and implementation guidelines
available on the internet) and to implement the methodologies
developed. It is also essential that the same level of importance
is placed on educating the staff working in the field to guar-
antee a direct clinical impact and to ensure high-level,
standardised medical care and related radiation protection ful-
ly exploiting and profiting from all research conducted with
regard to radiation protection in the medical field throughout
Europe. This aspect of the SRA is reflected in Chap. 4.
Background
Over the last 5 to 10 years the structure of research funding by
the European Commission (EC) has gradually changed. The
intention is to bring together all interested parties to facilitate
European research projects in the field of radiation protection
research and “to set up a European umbrella structure for the
administration of radiation protection research calls”. To this
end, SRAs have been developed or are currently under
development.
Therefore, a medical SRA is especially important in view
of the applications of ionising radiation in the medical field,
since the medical use of ionising radiation is the largest man-
made source of exposure to the human population. The ad-
vantages of such SRAs include:
& Providing guidance on/help to identify the most relevant
and urgent research topics in the fields they cover
& Demonstrating the importance of research areas to the
stakeholders
& Justifying research expenditure in defined areas
& Facilitating discussions with other members of the scien-
tific community in the field of radiation protection
& Determining important topics and influencing research
calls of the EC, OPERRA and CONCERT.
Since medical applications are among the most important
contributors to exposure of the population in Europe to ionis-
ing radiation, for medical radiation protection research to be
effective, it is critical that the results of the research projects
are directly transferred into clinical practice, i.e. translational
research.
This SRA has been the cornerstone for a common platform
of the European medical societies dealing with topics related
to the use of ionising radiation. In September 2016 the
European Alliance for Medical Radiation Protection
Research (EURAMED) was launched by EANM, EFOMP,
EFRS, ESR and ESTRO and is currently run as a joint initia-
tive under the umbrella of the European Institute for
Biomedical Imaging Research (EIBIR). The medium-term
goal is to establish EURAMED as a separate legal entity with
a sustainable governacne and membership structure to allow
other stakeholders to participate actively in the platform.
Updates are available at www.euramed.eu.
Research topics
Measurement and quantification in the field of medical
applications of ionising radiation
A key priority for radiation protection research in radiation
oncology, nuclear medicine and also interventional and
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diagnostic applications of ionising radiation is to improve
techniques and methods for measurement and quantification.
The research approaches will need to be multidisciplinary and
innovative. The key research questions in measurement and
quantification research are:
Characterisation of exposure
The basic quantity for the characterisation of exposure is the
absorbed dose, so whereever possible dose measurements or
calculations/calibrations should be stated in terms of absorbed
dose (1–3). One of the main challenges for future research is
the pronounced anatomical heterogeneity of (absorbed) doses
within and between critical organs in all areas of medical uses
of radiation. This needs to be supplemented by optimisation of
models and model parameters to translate absorbed doses into
equivalent, organ, biologically effective doses or any other
indirect dose entities. Accurate and precise measurements
with known uncertainty (4, ) are a prerequisite for the adequate
implementation of dosimetric techniques into medical practice
and medical routines, specifically for different types
(qualities) of radiation and levels of spatial resolution.
Therefore, the following issues need to be addressed in
research:
& Calibration of dosimeters for medical applications is cur-
rently performed using secondary standards non-specific
to the radiation fields used in medical application of ion-
ising radiation leading to undefined measurement uncer-
tainties. Therefore, exact measurements require calibra-
tion against radiation fields specific to medical
applications.
& There is a limited availability of dosimeters for use inside
the human body; this implies that currently simulations of
radiation transport and deposition are necessary, e.g. using
Monte-Carlo (MC) methods (6, 7), as is normalising them
to measured quantities.
& Real-time measurement of doses is relevant to reduce
doses to staff. Therefore, the development of specific do-
simeters is required, allowing real-time monitoring, e.g. of
eye structures and extremity/finger doses, from interven-
tional radiology/cardiology and nuclear medicine. The
existing dosimeters are either not for online measurements
or they suffer from technological limitations in terms of
highest dose rates as in pulsed radiation fields or size or
practicability.
& Non-uniform spatial (3D) and temporarily varying (4D)
dose distributions can lead to differences of up to several
orders of magnitude in local dose distributions (8).
Therefore, micro-dosimetric measurement devices and
techniques for use within and between cells, the anatom-
ical structures of organs and the human body are neces-
sary, e.g. for dosimetric use with regard to individual
structures in the eye, the brain and the heart, and also other
organs depending on the basis of future research results.
& Different types of radiation (photons, electrons, protons,
heavy ions, secondary neutrons) are used for and/or asso-
ciated with medical purposes. Correct determination of
doses to and dose-distributions within patients at different
levels of spatial resolution is necessary depending on the
required purpose in terms of radiobiological questions or
optimisation of procedures. Also mixed fields and energy
spectra need to be taken into account for reliable measure-
ments and calculations of dose-distributions.
& Knowledge on track structure and/or microdosimetry
of internal emitters (alpha, beta, Auger) is a prerequi-
site to predict the associated biological effects (9).
Therefore, computational methods need to be further
developed and connected to the results of correspond-
ing research on measurements and calibration proce-
dures (see above).
& Development of updated or alternative quantities and con-
cepts for describing the anatomical dose distributions
within organs, tissues and the body as the basis for
predicting health effects rather than mean absorbed doses
(e.g. dose averaged over an organ) or dose volume
histograms.
& Methodologies have to be developed for determination,
description measurement and calculation of doses outside
the planning target volume (PTV) for radiation therapy,
i.e. the peripheral dose. This is urgently required to build
and optimise prediction models for secondary tumours,
but also tissue effects, and to enable comparison of differ-
ent techniques and/or technologies.
This research would be a prerequisite for the accurate and
precise evaluation of the dose as the basis for better radiation
protection of the patient and medical personnel as explained
below.
Individual dosimetry
Individualised patient dose assessment methods, e.g. by ad-
justed phantoms for measurements (10), size-specific conver-
sion factors, dose measurements taking into account imaging
parameters shielding, etc., are needed to allow for accurate
patient dose estimation (2) and risk assessment (11). Many
dose distributions would depend on individual patient consti-
tution (e.g. size, weight, shape, age and biological factors such
as the distribution and kinetics of radioactive markers () or
susceptibility to different therapeutic procedures). Therefore,
the following dosimetric procedures need to be addressed in
research:
& Development of computational methods for dose distribu-
tion calculations based on patient-specific and equipment-
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specific characteristics for all medical procedures using
ionising radiation, including for example CT, interven-
tional and nuclear medicine procedures as well as
radiotherapeutic procedures avoiding different dose indi-
cators for different types of procedures in order to get
comparable meaningful information about organ doses
of individuals.
& Development of optimal measurement protocols in nucle-
ar medicine for accurate estimation of absorbed doses
using patient-specific and equipment-specific characteris-
tics. Refinement, validation and implementation of new
biokinetic models for dosimetry in molecular radiotherapy
using for example physiologically based pharmacokinetic
(PBPK) models for the individual assessment of
biokinetics (13), including uncertainty budgets (14).
& Development of methods to estimate or measure the actual
delivered radiation dose in radiotherapy.
& Development of a unique dose indicator that describes the
absorbed dose to organs in order to perform risk
assessment.
This research would be essential for accurate and precise
determination and evaluation of indication-, therapy- and/or
subgroup-specific doses and therefore risks of radiation-
induced morbidities of individual patients and thus on a per-
patient basis for better radiation protection of patients and
medical personnel.
Quality metrics for diagnostic imaging and therapy
For the use of quantitative imaging approaches, standardised
protocols for each clinical indication and/or specific disease
common clinical indication need to be developed (15).
Therefore, the following issues need to be addressed in
research:
& Development of dosimetric and image quality metrics to
fully assess the impact of novel detector technologies (e.g.
low or lowest noise as well as energy-resolving detectors)
and image reconstruction methods available for reducing
radiation exposure to the patients. To this end, research is
needed on which requirements (system stability, noise re-
duction, influence of individual patient characteristics, it-
erative reconstruction parameters) have to be met for
quantitative imaging to yield reliable and reproducible
results.
& Measuring methods (e.g. phantoms, reading protocols,
etc.) need to be improved or developed and standardised
to address the improvements in medical technology as
well as new methods, e.g. particle therapy or new molec-
ular imaging technologies.
& There is an increasing need also for quality metrics of
treatment plans to allow easier quality assurance to
facilitate comparability of methods used in radiation ther-
apy and to allow more standardised research regarding
clinical treatment outcomes.
& The concepts and the use of diagnostic reference levels
(DRLs) and achievable dose levels (ADLs) have to be
redefined to meet the requirements of organ-specific dose
distributions or critical organ structures doses.
This research enables the translation of quantitative tech-
niques to widespread clinical use for the benefit of the patient.
In addition, this research is also a prerequisite for the
harmonisation of practices and quality assurance.
Sources and influences of uncertainty
Uncertainties need to be determined for all techniques
described above, be it measurements or computations.
Many components independently contribute to the uncer-
tainty in the determination, reporting and performance of
medical applications and in its characterisation (4, 16). It
is of utmost importance to develop methods to assess the
contributions of different stages in the chain of medical
interventions to be able to define the relevant points of
optimisation, which means putting effort into those parts
of a medical application scheme where there is the highest
benefit. Therefore, the following issues need to be ad-
dressed in research:
& Quantification of the influence and sensitivity of different
parameters (technique dependent, system dependent, pa-
tient dependent, medical staff dependent).
& Development of methodologies for classifying different
influencing parameters and to build a system that allows
the optimisation of medical applications of ionising radi-
ation for individual patients or methods.
Knowledge of the integral uncertainty and its components
is key to identifying the most relevant steps, to allow for
prioritisation and targeted optimisation, thus making more ef-
fective use of clinical and research resources.
Normal tissue reactions, radiation-induced morbidity
and long-term health problems
A key priority for radiation protection research in radia-
tion oncology, nuclear medicine and also interventional
and diagnostic applications of ionising radiation is to im-
prove health risk estimates. The corresponding research
approaches will need to be multidisciplinary and innova-
tive. The key research questions in tissue reactions and
biological risk research are:
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Exposure-associated cancer risk: dose, dose distribution
and dose-rate dependence
Knowledge of the dose dependence of the radiation induction
of primary or secondary cancers, in particular in relation to
dose inhomogeneities and dose rate, is of major importance to
optimise therapeutic efficiency and reduce unwanted side ef-
fects. In radiation oncology, this refers to high doses within the
planning target volume (PTV) as well as to out-of-PTV doses,
e.g. low to moderate doses, in particular in intensity-
modulated and image-guided radiotherapy, but also in brachy-
therapy and molecular (radionuclide) radiotherapy (17). It also
needs to include other, additional treatment modalities, partic-
ularly chemo- and biologically targeted therapy. Diagnostic
procedures must also be considered, especially in view of
interventional or fluoroscopic procedures or nuclear medical
imaging techniques and those applied in preparation for
treatment.
Non-cancer effects in various tissues and radiobiology-based
effect models for individual morbidity endpoints
Radiation-induced morbidity (cancer and non-cancer diseases
and disorders) may be observed early or late (occurring after 3
months to 5 years after radiation exposure), not only in the
tissues and organs exposed to high doses. Also, very late
health effects (occurring after more than 5 years to many de-
cades after exposure) may not only be observed in high-dose
radiotherapy (>5 up to 50 Gy) but also in the intermediate (0.5
to 5 Gy) or low-dose (<0.5 Gy) ranges. Examples of these
very late occurring normal tissue morbidities, which may be
induced by localised radiation exposure outside the planning
target volume of radiotherapy or by repeated interventional
procedures, are: cardiovascular or cerebrovascular diseases,
functional or structural damage to eye structures, various de-
layed, persistent immunological changes, progressive micro-
vascular injuries, but also late and very late developmental and
functional detriments after radiation exposures in diagnostic
procedures and paediatric radiotherapy and many more
radiation-associated health disorders. The contribution of oth-
er treatment modalities, particularly chemo- and biologically
targeted therapy, to the development of very late side effects is
currently poorly understood and needs also to be considered
along with any diagnostic procedures, especially for interven-
tional or fluoroscopic and nuclear medicine procedures and
those applied in preparation for treatment.
Current morbidity risk models and normal tissue compli-
cation probability (NTCP) models are largely empirical or
based on hypothetical data-fitting models of assumed process-
es of damage development and lack the evidence of a mech-
anistic basis. Moreover, they do not consider the influence of
the position of the doses within one organ or the interaction of
dose distributions in “corresponding” organs, such as lung and
heart, or the effect of additional treatments, such as chemo-
therapy (18, 19). These factors, however, must be included to
get appropriate estimates for the patterns of risk of any indi-
vidual patient with regard to modern techniques in radiother-
apy, nuclear medicine and radiological diagnosis.
Individual patient-related radiation sensitivity and early
biomarkers of response and morbidity
The individual sensitivity of patients may be considered in the
choice of specific diagnostic procedures and/or therapeutic
strategies. This can be based on intrinsic factors (age, gender,
genomics, proteomics) of their tumours or different normal
tissues, but also on concomitant diseases impacting on general
or specific normal tissue tolerance, lifestyle (e.g. reduced
lung/liver tolerance due to smoking and alcohol consumption)
or previous/parallel treatments.
In a number of tumours, biological factors affecting radio-
sensitivity, i.e. predictive factors, such as local hypoxia, tu-
mour heterogeneity, or viral infections, were identified. Such
investigations need to be extended and may also consider the
early response of the tumour to a specific treatment. Imaging
biomarkers of tumour radiosensitivity are needed in this con-
text, as well as biomarkers of morbidity, which can be identi-
fied before or early in the treatment phase and may help in the
selection of the adequate treatment of the individual patient.
These have so far been rarely studied. However, patients with
a high risk for a certain, severe, morbidity symptom may re-
quire a change in dose distribution or in treatment strategy, or
follow-up protocols may need to be adjusted to the individual
morbidity risk pattern based on early biomarker expression ().
Radiobiological mechanism of radiation-induced side effects
and protective strategies
The radiobiological molecular mechanisms of radiation-
induced morbidities in normal tissues and organs are very
complex and vary between different signs and symptoms of
morbidity in the same organ and between different organs.
Also the tumour responses to therapeutic exposure to ionising
radiation, including radiotherapy using hadrons, are currently
largely unknown. The radiobiological molecular mechanisms
are even more complex for combined radiotherapy and
chemo- or biologically targeted treatment strategies. These
mechanisms need to be clarified for specific clinical morbidity
endpoints in order to develop specific strategies for protection,
mitigation or management of the clinical consequences of
exposure. They are even more important for medical radiation
procedures in paediatric patients given the evidence showing
that the complexity and severity of morbidities and develop-
mental injury and the risks of therapy-induced malignant dis-
eases are particularly high after radiotherapy (in almost all
instances in combination with chemotherapy).
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Similarly, novel strategies for improving the diagnostic
and/or therapeutic efficacy for the application of ionising ra-
diation may be based on the synergistic combination with
upcoming technologies such as combinations with high-
intensity focussed ultrasound and biology-based approaches
relying on tumour genomics, proteomics or metabolomics in-
cluding local enhancement of drug delivery.
Both the protective and sensitising strategies need to be
established and validated in preclinical as well as in subse-
quent clinical studies. These investigations need to focus on
the efficacy of the novel approaches and also on their selec-
tivity for the respective target tissue to guarantee a therapeutic
gain.
Optimisation of radiation exposure and harmonisation
of practices
According to the European Basic Safety Standard (BSS)
(2013/59/EURATOM) (21), the radiation protection of indi-
viduals subject to public or occupational exposure must be
optimised with the aim of keeping the magnitude of individual
doses, the likelihood of exposure and the number of individ-
uals exposed as low as reasonably achievable (ALARA) tak-
ing into account the current state of technical knowledge, eco-
nomic and societal factors. The optimisation of the protection
of individuals subject to medical exposure should be consis-
tent with the medical purpose of the exposure.
The EU Directive on patients’ rights in cross-border
healthcare (2011/24/EU) (22) calls for a concerted strategy
in terms of harmonisation of clinical practices, meeting pa-
tients’ expectations of the highest quality healthcare, including
when they seek treatment away from home.
According to the literature, high variability of mean effec-
tive doses or organ doses of patients across Europe persists
across all medical ionising radiation procedures and is seen
across single countries, hospitals or even at the departmental
level (23), despite technological developments facilitating re-
ductions in patient dose, thus highlighting the importance of
harmonisation of ionising radiation procedures and the devel-
opment of new and more efficient optimisation methods in-
cluding evaluation criteria. For this optimisation, there needs
to be a general definition as to what is an acceptable level of
quality, what kind of optimisation should be performed and
what is the optimal level. With the main goal of maximising
the clinical outputs of the procedures while minimising the
exposure of patients and staff, the key research questions are:
Patient-tailored diagnosis and treatment
The comprehensive tailoring of imaging and therapeutic pro-
cedures in terms of the clinical question, anthropometric and
physiological parameters of each patient, especially children,
and lesion-specific characteristics is a key challenge that is
largely yet to be fully addressed. Furthermore, imaging is
essential to patient-tailored therapy planning, therapy moni-
toring and follow-up of disease, as well as targeting non-
invasive or minimally invasive treatments, especially with
the rise of theranostics (combination of diagnostic and thera-
peutic procedures to optimise treatment).
For the reasons given above, and in view of reducing radi-
ation exposure to the patients by individually tailoring their
diagnosis and treatment, research needs to be conducted with
regard to the following currently unresolved issues:
& Development of quantitative imaging biomarkers for each
common clinical indication and/or specific disease/organ
and their standardisation with regard to required image
quality in conjunction with related radiation exposure.
& Recent advances in imaging using specific radiotracers
will provide additional tools for better characterisation of
a lesion at the molecular level. This will provide an insight
into lesion heterogeneity and targeting, with perspectives
in guiding biopsy of lesions, prediction of treatment re-
sponse and image-guided therapy.
& For optimal treatment prescription in targeted radiothera-
py the knowledge of the dose-response relationship is es-
sential. In targeted radiotherapy, patient-specific dosime-
try is essential for both the prediction of the adverse events
of a treatment and of the tumour response (24).
& Research on the requirements that have to be met for
quantitative imaging to yield reliable and reproducible re-
sults, e.g. in view of system stability, image reconstruction
techniques, influence of individual patient characteristics
and applied radiation exposure.
& Development of approaches for low-dose time-resolved
volumetric imaging (4D), e.g. of blood flow or volume
distribution (perfusion) as well as organ-motion depen-
dent imaging, especially in view of therapy planning and
treatment response imaging.
& Development of body-mass index (BMI)-specific image
acquisition protocols and specific dose-reduction algo-
rithms for obese patients, since obese patients require
higher than average radiation doses, and exploitation of
techniques normally used for radiation exposure reduction
to achieve diagnostic image quality.
& Development of approaches for low-dose treatment re-
sponse and follow-up imaging solely focussing on the
detection of “change” (relative to a standardised baseline
acquired at higher radiation exposure) providing reliable
diagnostic assessment, e.g. through development of
standardised disease- or treatment-specific imaging proto-
cols especially for those patients frequently imaged.
& Research for identifying underlying relationships among
demographic, disease-related and ‘omics’ biodata and im-
age and treatment data for fully developing personalised
medicine in order to offer the best medical diagnostics and
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treatment associated with the lowest possible dose to each
individual patient.
The benefit of this research could be to develop systems for
diagnosis and treatment allowing for more efficient treatment
techniques, which may also offer economic benefits. This re-
search could also provide further insights into disease process-
es of individual patients and therefore foster precision
medicine.
Full exploitation and improvement of technology
and techniques
Despite the potential for the exponential growth in the tech-
nological features of medical imaging equipment to decrease
patient doses, such benefits are not always realised in daily
clinical practice (25).
Therefore research on development, improvement, clinical
applicability and full clinical exploitation of (new) technology
and techniques for offering diagnosis and treatment delivery
associated with the lowest technically possible radiation ex-
posure to the patients is required. In this context, currently the
following topics need to be addressed by research:
& Low-dose CT imaging enabled by low tube potentials and
current-time products in view of its clinical applicability,
indication, standardisation as well as its potential diagnos-
tic and technical limitations.
& Novel image reconstruction techniques enabling low- or
lowest-dose image acquisitions, with regard to their rou-
tine clinical applicability and their limitations in view of
ensuring diagnostic accuracy and reliability.
& Novel detector technology in medical imaging in view of
its clinical applicability and potentially associated techni-
cal limitations.
& Diffraction enhanced imaging and other newly developed
approaches.
& Further development, implementation and application of
patient- and disease-adapted techniques and protocols of
combined modalities as for example SPECT/CT (26),
PET/CT, PET/MRI and LINAC-MRI.
& Optimisation of image guidance procedures in
radiotherapy.
& Strategies for a reduction in peripheral doses in radiother-
apy, e.g. by defining indications for ion therapy.
& Research for, and production of, novel radionuclides and
radiopharmaceuticals for either improving diagnostic and
therapeutic outcome or reducing associated exposure.
& Data-crawling and -mining approaches based on large-
scale data contained in imaging and treatment biobanks,
e.g. for extracting indication-specific acquisition or treat-
ment protocol parameters along with associated patient
exposure data for the purposes of diagnosis and treatment
optimisation, standardisation and harmonisation (through
the definition of European DRLs) as well as for extraction
of higher-order patterns of disease, its diagnostics and
treatment along with associated doses, and the possible
interrelation of this data, e.g. to genomic data
(radiogenomics).
While research with regard to technology development may
remain basic research that is institution- or manufacturer-
driven and controlled, though requiring and relying on input
and feedback from medical research and routine clinical appli-
cations, research on clinical applicability, improvement and
full exploitation of technology and techniques enabling radia-
tion exposure reduction is driven by, and requires, active med-
ical research in the fields of radiological diagnosis and radio-
pharmaceutical and therapeutic treatment. There needs to be an
emphasis on the close link between technology developments
at research institutions, especially at manufacturers’ sides, and
the clinical research facilities with feedback options and espe-
cially to define a process to consolidate the achievements in
terms of harmonisation.
Any optimisation inmedical imaging techniques, including
dose reduction strategies, must be evaluated thoroughly in
terms of the resulting image quality. In determining whether
an image is diagnostic or fit for purpose, it is important to take
into account not only the physical measurements of image
quality [e.g. signal-to-noise ratio (SNR), modulation transfer
function (MTF) and detector quantum efficiency (DQE)] but
also to include psychophysical methods (e.g. contrast detail
assessment and spatial resolution assessment) and clinical,
diagnostic performance approaches such as visual grading
analysis (VGA), receiver-operating characteristic (ROC) and
psychometric scales. The current variability and absence of
validated approaches and guidelines represent a significant
barrier to effective optimisation research. The 1996
European Guidelines on Quality Criteria for Diagnostic
Radiographic Images (27) aimed to provide some assistance
with image quality assessment but these were very limited,
have deficiencies, were never validated and are now dated.
There is thus an urgent need for establishment of robust, val-
idated approaches to facilitate this critical aspect of optimisa-
tion research.
Technologically meaningful developments, with re-
spect to the possible output for patient, staff and public,
are at varying levels of maturity in terms of a technologies
status as a product line and their applications in the med-
ical environment.
In this context, multi-professional engagement together
with educational institutions and equipment manufacturers
will facilitate the required development of strategies for the
harmonisation of ionising radiation procedures and standards
of practice, since several studies have highlighted the hetero-
geneous use of technology and the unanticipated patient and
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staff dose increases. This is of particular importance in paedi-
atric populations as well as for patient cohorts requiring mul-
tiple consecutive diagnostic, radiopharmaceutical or therapeu-
tic procedures.
Clinical and dose structured reporting
Clinical reporting: Medical imaging procedure workflow in-
volves several steps, ending with a clinical report. Currently,
medical imaging reports are often presented with little or no
structure to the text. This can present difficulties in under-
standing the content of the report for both referring physicians
and patients. The development of a structured reporting sys-
tem will improve the clinical outcome of a medical imaging
procedure, by focussing on the essential message, in a
harmonised way, thus facilitating the communication process
along the clinical pathway of the patient.
There are many advantages of such reports, including im-
proved follow-up for returning or chronic patients, easy re-
trieval of pertinent information enabling clinical and transla-
tional research, integration of the information in imaging
biobanks and automated translation.
Another related issue is the lack of a centralised med-
ical databank on imaging procedures for each individual
patient on a national and European level, often leading to
unnecessary repeated diagnostic procedures and hence un-
necessary radiation exposure. Harmonisation of clinical
reports could facilitate the development of such a
centralised medical registry at a European level. Also, a
centralised dose data collection algorithm for therapeutic
procedures would allow for improved analyses of dose-
effect relationships for adverse events, including stochas-
tic radiation sequelae.
Dose reporting: Structured dose reporting in radiation di-
agnostics and therapy (or documentation of administered
activities in nuclear medicine) is a growing area of focus
and will benefit all professions directly involved in the
ionising radiation procedures and patients undergoing
such procedures in the years to come. However, the ade-
quate specification of dose distributions has not been ad-
dressed yet in research and clinical practice sufficiently
(1). In radiation oncology structured dose reporting needs
to address absorbed doses in organs at risk and/or at their
subvolumes, relevant for adverse event endpoints. The
latter needs to be specified and their scaling to be defined.
Moreover, anatomy-related dose distributions in the irra-
diated volume and in the periphery, at least down to the
1% isodose, need to be reported or re-constructible from
the documented treatment information and then specifical-
ly related to potential radiation sequelae.
The main benefits would be:
& To establish a model for providing information, in radia-
tion diagnostics and nuclear medicine, about patient dose
exposure in an easily accessible way (e.g. by integrating
visual scales for the referring physicians to understand the
level of exposure).
& To facilitate the rapid determination of local, national and
European DRLs.
& To facilitate establishment, in radiation oncology, of dose
response relationships for adverse events in organs at risk
as well as for stochastic radiation effects both close to the
PTVand in the periphery of the patient.
Structured dose reporting in radiation diagnostics (or doc-
umentation of administered activities in nuclear medicine) is
an essential tool for the harmonisation of the dose manage-
ment systems and the comparison of doses, creating a com-
prehensive, common language for health professionals.
Structured dose reporting in radiotherapy is essential to estab-
lish firm dose-effect relationships for adverse deterministic
and stochastic events.
Protection of staff, patients, carers and the general public
Aside from the optimisation of protocols and procedures, their
standardisation and their personalisation, it is most important
to optimise radiation protection using existing radiation pro-
tection measures (28). To optimise radiation protection in
terms of applicability and best benefit for staff and patients,
the establishment of key indicators of safety and quality in
radiation protection is essential according to the general
ALARA principle discussed before. The primary goal of the
development of safety programmes is to reduce morbidity
risks from excessive exposure to ionising radiation for specific
procedures and populations, e.g. interventional radiology and
the paediatric population. Another focus is on cost-benefit
analysis of the implementation of radiation protection devices
and safety programmes. Neither proven criteria of cost nor
proven criteria of benefit have been established so far.
Research must explore both external and internal radiation
exposure and their associated protection measures.
Justification of the use of ionising radiation in medical
practice
The principle of justification is one of the key pillars of radi-
ation protection underlined in the recently revised European
BSS Directive (21). This principle focusses on weighing the
benefits versus the risks. Further important elements are pa-
tient communication, as the basis for shared decision-making
including the patient rights for influencing the decision, as
well as the appropriateness of the radiological procedure with
respect to the clinical setting. The key research questions in
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research into the justification of the use of ionising radiation in
medical practice are:
Benefit/risk assessment and communication
While the clinical benefit of a diagnostic or interventional
imaging procedure is assumed to be established, an estimation
of the risk related to effective dose exposure for a given patient
is a difficult step because the current estimations are for a
general population. The current uncertainties in this area make
the establishment of a reliable benefit/risk assessment virtually
impossible.
Therefore there is the urgent need for research aimed at risk
estimation for an individual patient. However, it is unclear
how this can be implemented for the stochastic mechanisms
based on epidemiologic data. Increased risk factors for organ-
specific patient groups or patient-parameter-based changes on
optimal imaging procedure setups may however be investigat-
ed. For the development of such a research programme for
diagnostic imaging and interventional procedures, reference
to a centralised repository of imaging data would be an im-
portant resource for data mining and the following risk assess-
ment (see Sects. 3.5.1 and 3.5.2).
The proposed research will have a direct benefit for the
patient in general and especially in the context of screening
methods based on the use of ionising radiation.
Most new therapeutic radiation technologies are clinically
introduced to reduce exposure to healthy tissue. In the near
future, an increasing number of cancer patients will be treated
with particles (e.g. protons and carbon ions). Although parti-
cle therapy will result in lower dose levels to many critical
structures as compared to the currently used photon-based
technologies, the consequences in terms of reduction of late
and very late side effects remain to be determined and have to
be weighed against the higher costs.
In the context of the current drive for patient empowerment
and involvement in the decision-making process, the develop-
ment and subsequent evaluation of novel tools for patient
communication have become necessary. Some professional
organisations such as the ACR, ESR, RSNA and national
clinical societies have developed communication guidelines
and platforms for diagnostic imaging; however, a unified ap-
proach regarding methodology and content is currently
missing.
The proposed research work will aim to develop a
European evidence-based electronic communication platform
focussing on all types of diagnostic imaging using current
information technology that is endorsed by the relevant pro-
fessional organisations, patient organisations and other rele-
vant stakeholders. The European platform will be designed in
a way to allow for localisation and adaptation to the national/
regional settings. The establishment of such a system has to be
based on the successful completion of the cost-benefit re-
search activities outlined above.
Improvement of use of evidence-based guidelines
Clinical imaging guidelines are intended to help physicians
decide when an imaging study would be useful and identify
the most appropriate examination for a particular patient. In
recent years, imaging guidelines, in view of the referral pro-
cess, have received much attention from the radiation protec-
tion community and international organisations given the in-
creasing number of medical imaging procedures and studies
that have shown that about 30% of the imaging procedures
performed in Europe were found to be inappropriate (29). The
recently revised European BSS Directive (27) requires that
clinical imaging guidelines are available in all EU Member
States.
In 2011, the European Commission awarded a European
tender project to assess the availability and implementation of
clinical imaging guidelines in EU member states. One of the
key conclusions, also highlighted in subsequent studies, was
the recommendation that the awareness and use of clinical
imaging guidelines in Europe need to be improved and novel
approaches are needed for that purpose (30).
The proposed research work should identify and develop
methods to improve the use of clinical imaging guidelines in
Europe especially in view of the referral process at large, e.g.
through incentives, regulatory requirements, IT tools, etc. The
research work is related to a key priority in medical radiation
protection as outlined among others in the Bonn Call for
Action (31) and must be relevant for all diagnostic applica-
tions of ionising radiation. To define the proposedmethods, an
evaluation and impact assessment of the use of currently
existing European and national guidelines must be performed
with an emphasis on evaluating the usability of the guidelines
and their impact on daily clinical practice (29, 32).
The outcome of the proposed research work should be a
European recommendation paper on how to improve the dis-
semination, integration into the clinical workflow and use at
large of clinical imaging guidelines in view of the referral
process. In addition methodologies and guidelines for adop-
tion/localisation/adaptation of the guidelines need to be
proposed.
The recommendation paper shall serve as guidance for pro-
fessional societies and policy-makers in Europe.
Infrastructure for quality assurance
To perform investigations on tissue reactions, optimisation
procedures as well as risk and benefit evaluations, it is
important to rely on optimal, quality assured data, which are
gathered under defined conditions and which are necessary for
various reasons including legal questions pertaining or
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specific to the research to be performed. In addition, the
clinical system of medical applications of ionising radiation
has to be standardised (33) and evaluated concerning its effec-
tiveness in radiation protection.
Data coding, collection and management
It is crucial for the future of medical imaging in Europe to
develop a European medical imaging coding system
(EMICS) including radiology and nuclear medicine imaging
procedures. EMICS should apply to all medical procedures
based on ionising radiation, giving policy makers and
healthcare providers an objective and clear view, on a
procedure-level basis, at the national and EU levels. This
would be a fundamental tool for future studies such as popu-
lation dose studies and/or parameter-dependent image quality
studies. According to the recently published Dose DataMed 2
report “in order to compare x-ray examination frequency data
between countries, and to assign typical effective dose values
to examinations, it is crucial that an ‘X-ray examination’ is
defined and counted in a consistent way” (34). Therefore, the
development of EMICS, based on an alphanumerical code
structure, must be facilitated and must be integrated into all
HIS/RIS systems.
EMICS would also support the harmonisation of the “lan-
guage” for medical imaging and therapy across Europe giving
healthcare providers a powerful tool for the future planning of
health systems at local, regional, national and European
levels. This should be extended to the acquisition of data on
the long-term consequences of radiation exposure, diagnostic
or therapeutic, potentially in combination with other therapeu-
tic procedures, to allow structured long-term follow-up, as-
sessment and documentation of treatment-related morbidity
and the possibility to relate morbidity to anatomical dose dis-
tribution. Requirements and structures, along with administra-
tive characteristics, including data protection issues, need to
be defined. Such data management structures will provide a
basis for epidemiological investigations into relevant medical
questions. Data should be collected throughout Europe ac-
cording to this standard using defined mandatory and where
possible additional data regarding exposure and if possible
image quality as well as certain patient-specific data.
Comprehensive medical database/imaging biobank
Biobanks are repositories for the storage and retrieval of bio-
logical samples of a large number of subjects. A major goal of
biobanks is the organised collection of biological material and
associated information to spread access among scientists re-
quiring this information. Extending this concept to medical
imaging and especially to radiation protection is needed to
collect radiation protection metrics and to allow for long-
term follow-up for specific cohorts, which will be called a
comprehensive medical database or imaging biobank. It might
be important for various reasons:
Importance for dose collection: The concepts and the use of
DRLs and achievable dose levels (ADLs) have to be redefined
to meet the requirements of organ-specific dose distributions
or critical organ structure doses as mentioned in Sect. 3.1.
Large-scale (national, regional) patient inter- and intra-organ
dose distribution monitoring is necessary for the purpose of
definition, optimisation and periodic assessment of DRLs and
ADLs. This aim can be achieved by developing large-scale
archives and automatic data analysis using the recently devel-
oped standards allowing sending and archiving of dose
information.
The development of automatic methods for phantom image
quality assessment (and patient image quality assessment) to-
gether with the use of advanced IT technologies (e.g. large-
scale archives, data-mining methods, expert system tech-
nique) is required for supporting users in the optimisation
process.
Importance for long-term follow-up of cohorts: There is clear
evidence that radiotherapy may cause, in organs and tis-
sues close to the PTV but also in organs in the periphery,
an increased risk for late and very late side effects that are
clinically relevant and have a major impact on quality of
life. Although there is an increasing awareness of
radiation-induced very late side effects, the infrastructure
to systematically collect relevant data to get more insight
in the factors that contribute to these risks is largely
lacking.
The proposed research work should involve the develop-
ment of a structure for a European imaging biobank infrastruc-
ture integrated with a European radiation oncology biobank
infrastructure.
Developing key performance indicators for quality and safety
Key performance indicators (KPIs) have been successfully
introduced as a performance measurement in many areas of
healthcare in line with the EU Agenda on Quality of Health
Care and Patient Safety put forward by the EC DG SANTE.
Currently there is no recognised gold standard in the fields of
medical imaging or radiation therapy. A general concept of
performance indicators for imaging and radiation therapy is
thus needed and should also include indicators for the safety
of patients and of procedures and how to maintain safety stan-
dards, according to the optimisation and justification
processes.
The proposed research work will consist in the establish-
ment of KPIs for the quality achieved regarding specific med-
ical procedures and in general terms of radiation protection
and harmonisation at the European level. For integration into
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the workflow, pilot studies in dedicated centres and impact
assessment before dissemination are envisaged.
Audit systems
Clinical audit is a tool designed to improve the quality of
patient care, experience and outcome through formal re-
view of systems, pathways and outcome of care against
defined standards, and the implementation of change
based on the results. Audit cannot be carried out without
a preset standard against which performance can be
assessed.
As laid down in the revised European BSS Directive (21),
Member States shall ensure that clinical audits are carried out
in accordance with national procedures. Clinical audit is a
relatively new concept in radiation protection. It seeks to im-
prove the quality and outcome of patient care through struc-
tured review of medical radiological practices, procedures and
results, whereby these are examined against agreed standards
for good medical radiological procedures, with modification
of practices, where appropriate, and the application of new
standards if necessary.
In October 2009, the EC published guidelines relating
to clinical audits for radiological practice, including all
investigations and therapies involving ionising radiation
(35). In spite of this document, clinical audit is still clear-
ly underdeveloped in Europe. To address this shortcom-
ing, the proposed research must aim to develop an easy-
to-use, cost- and time-effective European clinical audit
tool taking into account existing initiatives from profes-
sional organisations. The tool will facilitate implementa-
tion of the relevant requirements in the European BSS
Directive and could potentially provide the basis for fu-
ture European accreditation processes based on quality
and safety.
Education and training metrics
There is a strong demand for new education and training
models in medical radiation protection because of the rapid
development of medical techniques based on ionising radia-
tion, growth of hospitals and the continuous need to produce
competent health professionals. The major challenge is ad-
dressing the variety of professions and professionals, with
different knowledge background and different needs, but all
working towards the same objective: patient and staff safety
(36, 37).
To achieve that objective it is necessary to establish a
harmonised and sustainable safety culture in radiation
protection amongst health professionals through
specifically oriented education and training courses.
External assessment of the quality of education or
training provision is needed (37) and should be provided
by a European accreditation body.
It is important to develop through research:
& A metric system to measure the knowledge, skills and
competence outcomes from education and training in ra-
diation protection for the different health professions in-
volved in ionising radiation procedures.
& An assessment system to measure:
– the impact of the implementation of a continuous profes-
sional development model for education and training in
radiation protection;
– the type of needs for education and training, considering
the installation of new equipment and/or new procedures.
There is a need to create a European certification system for
education and training in radiation protection, based on the
development of standards of proficiency for health profes-
sionals, as an instrument to guarantee safety procedures to
European citizens, through harmonisation of practice through
education and training.
Education and training
As highlighted in the recent EC Radiation Protection No. 175
‘Guidelines on radiation protection education and training of
medical professionals in the European Union’ there is a con-
tinuing and growing need for high-quality education and train-
ing in the field to ensure the radiation protection of patients,
staff and the public. This education and training must be ac-
cessible and delivered at an appropriate level for all profes-
sionals working in the field of medical ionising radiation as
well as those utilising the services provided by medical ionis-
ing radiation professionals. EC Radiation Protection No. 175
came about as an outcome of the MEDRAPET project and
describes education and training in radiation protection using
the European qualifications framework (EQF), knowledge,
skills and competence (KSC) structure and European credit
transfer system (ECTS) (38).
It is essential that any research in the area of medical ion-
ising radiation is translated into clinical practice to ensure that
patients and staff see the direct benefits of this research. As
highlighted in Sects. 3.3 and 3.4 of this SRA, there is evidence
that this translational research often fails because of the ab-
sence of parallel education and training programmes. High-
quality education and training programmes will raise aware-
ness of ongoing EU research projects and initiatives and en-
sure their uptake into clinical practice at local, national and
European levels. Separately, there has been an identified need
to also develop high-quality education and training
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specifically for researchers to help strengthen the medical ion-
ising radiation research community.
Education and training may consist of traditional, face-to-
face lectures and practical sessions but should also focus on
becoming more clinically focussed and case based. Online, or
e-learning, approaches to the delivery of content at all levels
utilising mobile devices is a key consideration, which includes
the development of dedicated appropriate e-learning tools, e.g.
facilitated by a multidisciplinary European e-learning
platform.
Education of staff
In the former chapters necessary and relevant topics for re-
search related to the optimal use of ionising radiation and
radiation protection in medical applications have been ex-
plained. Also, measures have been mentioned concerning
how these optimisation have to be implemented throughout
European by means of standardisation and harmonisation.
However, it is obviously not sufficient just to define methods
for harmonisation but this has to be reflected within the edu-
cation of the staff (28, 39).




& radiation communication and
& specific parts for the procedures/areas that are supposed to
be covered by the staff.
Therefore, within this SRA it is proposed to develop a
standardised education rule describing topics that have to be
covered. In addition there is a need for securing the highest
level of knowledge transported reflecting state-of-the art tech-
nology as well as standardisation and harmonisation efforts.
Finally, establishment of a European certification approved by
the medical societies issuing this SRA should also be covered,
not only after the completion of initial training, but also
throughout the whole professional life of each professional.
Education of researchers
To provide valuable research dealing with these identified
relevant topics with potential impact, it is important to
perform well-founded and structured research along cer-
tain lines. To do so, it is also necessary to train re-
searchers in performing research according to the best
practice. This especially holds true for research working
with humans or biological material, but also with any data
related to humans. There has to be a standardised training
structure also reflecting the actual state of the art for re-
search procedures with the goal of fostering the efficiency
of projects reflecting the research topics identified above
especially in terms of optimal patient care and radiation
protection.
In this respect it is important to deal with best practice
regarding:
& literature and citation practices;
& statistical power of investigations;
& uncertainty budget calculation of measurements and cal-
culations/simulations;
& clear hypothesis-driven project definition;
& pre-research feasibility estimates of proposed outcomes.
ACR, American College of Radiology; ADLs, Achievable
Dose Levels; ALARA, As Low As Reasonably Achievable;
ALLIANCE, European Radioecology Alliance; BMI, Body-
Mass Index; BSS, Basic Safety Standard; CT, Computed
Tomography; CONCERT, European Joint Programme for
the Integration of Radiation Protection Research; DE, Dual-
Energy; DRLs, Diagnostic Reference Levels; EANM,
European Association of Nuclear Medicine; EC, European
Commission; ECTS, European Credit Transfer System;
EFOMP, European Federation of Organisations in Medical
Physics; EFRS, European Federation of Radiographer
Societies; EMICS, European Medical Imaging Coding
System; EQF, European Qualifications Framework; ESR,
European Society of Radiology; ESTRO, European Society
for Radiotherapy and Oncology; EU, European Union;
EURADOS, European Radiation Dosimetry Group;
EURAMED, European Alliance for Medical Radiation
Protection Research; HIS, Hospital Information System; IR,
Interventional Radiology; IT, Information Technology; KPIs,
Key Performance Indicators; KSC, Knowledge, Skills and
Competence; LINAC, Linear Accelerator; MC, Monte
Carlo; MEDRAPET; Medical Exposures Directive’s
Requirements on Radiation Protection Training of Medical
Professionals in the EU; MELODI, Multidisciplinary
European Low Dose Initiative; MRI, Magnetic Resonance
Imaging; NERIS, European Platform on Preparedness for
Nuclear and Radiological Emergency Response and
Recovery; NTCP, Normal Tissue Complication Probability;
OPERRA, Open Project for European Radiation Research
Area; PBPK, Physiologically-based Pharmacokinetic; PET,
Positron Emission Tomography; PTV, Planning Target
Volume; RIS, Radiology Information System; RSNA,
Radiological Society of North America; RTD, Research and
Technological Development; SPECT, Single Photon
Emission Computed Tomography; SRA, Strategic Research
Agenda; TCP, Tumour Control Probability
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